JJH-201601

N/A

Report date: 2025/07/10 14:09:09
NME

Base Information

Drug NameJJH-201601
Drug Alias NameJJH-201601
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSignal transducer and activator of transcription 3 inhibitorsBromodomain and extra terminal domain protein inhibitors
TargetsMicrotubule-associated proteinsBromodomain and extra terminal domain protein
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsBile Duct Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Giber Pharmaceutical Co LtdShanghai Jiaotong University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJiangsu Giber Pharmaceutical Co Ltd
Inactive CompaniesShanghai Jiaotong University
Active IndicationsSolid tumoursPancreatic NeoplasmsBile Duct Neoplasms +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A